AML and HR-MDS have higher levels of CD47 than normal hematopoietic stem cells, contributing to the poor prognosis by enabling the evasion of phagocyte-mediated immune surveillance [58,59]. The gene discussed is CD47; the disease is acute myeloid leukemia.